Since then I have taken AZT, ddI, d4T, Crixivan, Viracept,
Viramune, Bactrim, Megace, and others.
(17.)
Viramune [package insert], Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc.; 2017.
The company says that it has distributed almotriptan tablets USP, 6.25 and 12.5, the generic version of Janssen Pharmaceuticals' Axert used for the treatment of migraine attacks as well as for nevirapine extended-release tablets, 100 mg, the generic version of Boehringer Ingelheim Corp.'s
Viramune XR.
Mylan, a global generic and specialty pharmaceuticals company registered in the Netherlands, has launched its Nevirapine Extended-release Tablets, 100 mg, the generic version of Boehringer Ingelheim's
Viramune XR, in the United States, it was reported yesterday.
tech-res.com/Document/DrugInfoDoc/PLNevirapine (
Viramune)PI_Nov2012.pdf [accessed June 22, 2013].
Treatment regimens included d4T (stavudine (Zerit)) or AZT (zidovudine (Retrovir)) with 3TC (lamivudine (Epivir)) and either efavirenz (Sustiva or Stocrin) or nevirapine (
Viramune).
The
Viramune (nevirapine) syrup opposition case set an important precedent for all future ARV patent oppositions in India.
In 2008, for instance, the Indian Patent Office rejected a patent application for
Viramune Suspension (nevirapine hemihydrates), a syrup form of
Viramune (nevirapine), which is important for children living with HIV who are unable to swallow tablets, as a "new form" of a "known substance".
They include delavirdine (Rescriptor), efavirenz (Sustiva, Stocrin), nevirapine (
Viramune) and etravirine (Intelence).
Cameroon on January 2005, issued compulsory licenses for HIV/AIDS drugs Nevirapine,
Viramune Lamivudine (brand name 3TC*) and fixed dose combinations of Lamivudine and Zidovudine (brand name Combivirt).
In 2004, Boehringer-Ingelheim, manufacturers of NVP (
Viramune) performed a retrospective analysis of hepatoxicity events and found no consistent CD4 cell-count cut-off that could be identified in women, that was associated with an increased risk of liver enzyme elevations.
Significantly more people taking a nonnucleoside (such as Intelence, Sustiva, or
Viramune) met the HDL cholesterol goal than did people taking a protease inhibitor (such as Kaletra, Prezista, or Reyataz) (40% versus 25%).